Overview
Cagrilintide is a long-acting amylin analog in clinical development for weight management, often studied in combination with semaglutide (the combination is referred to as CagriSema).
How It's Thought to Work
Amylin is a hormone co-secreted with insulin that promotes satiety and slows gastric emptying; cagrilintide is designed to mimic those effects with a long duration of action.
What the Research Says
Supported by ongoing human clinical trials, including combination studies with semaglutide. It is not yet approved.
Regulatory & Legal Status
Investigational — not FDA-approved. Any consumer 'research chemical' version is unapproved and unregulated.
Safety Considerations
Long-term human safety is still being established in trials. Not available as an approved medicine. Consult a clinician.